Skip to main content
. 2023 Jan 9;12:1036906. doi: 10.3389/fonc.2022.1036906

Figure 1.

Figure 1

Clinical outcomes. (A), ORR and DCR of the biosimilar and reference groups. (B), ORR of patients treated with bevacizumab (or biosimilar) in combination with chemotherapy and immunotherapy. (C), ORR of different number of treatment lines in the two groups. (D), ORR of patients with or without radiotherapy in the two groups. (E), ORR of different combined treatment regimens in the two groups. (F), DCR of patients with or without brain metastases in the two groups. * P<0.05.